Connect with us

Business

US lawmakers accuse Pfizer, Eli Lilly of testing new drugs on prisoners in Communist China

Published

6 minute read

From LifeSiteNews

By Calvin Freiburger

Two Republicans and two Democrats in the House of Representatives have leveled stunning allegations against two pharmaceutical companies, calling on the U.S. Food and Drug Administration to investigate potential testing of drugs on prisoners of Communist China.

A bipartisan group of Congress members has leveled stunning allegations against pharmaceutical companies Pfizer and Eli Lilly, calling on the U.S. Food & Drug Administration (FDA) to investigate the potential testing of new drugs on prisoners of Communist China.

The letter was sent August 19 to FDA Commissioner Dr. Robert Calf and signed by Select Committee on the Chinese Communist Party (CCP) Chair Rep. John Moolenaar, a Republican from Florida and ranking member and Illinois Democratic Rep. Raja Krishnamoorthi, Health Energy & Commerce Subcommittee ranking member and California Democratic Rep. Anna Eshoo, and Florida Republican Rep. Neal Dunn.

“For over a decade, it appears that U.S. biopharmaceutical companies conducted clinical trials with China’s military organizations, and specifically with medical centers and hospitals affiliated with the People’s Liberation Army’s (PLA), to determine the safety and effectiveness of new drug candidates prior to approval,” the letter reads. “ … we are also concerned that U.S. biopharmaceutical companies have conducted clinical trials with hospital infrastructure located in the Xinjiang Uyghur Autonomous Region (XUAR), where the Chinese Communist Party (CCP) is engaged in genocide of the Uyghur population.”

The lawmakers’ review of publicly available data found that over the last decade major American Pharma companies have conducted “hundreds of clinical trials in China that included at least one entity with PLA in the name as a research trial partner.”

“Even today, one major U.S. biopharmaceutical entity is actively recruiting patients for an advanced Alzheimer drug trial and is partnered with the PLA’s General Hospital and Medical School … and the PLA’s Air Force Medical University. … Previously, another U.S. biopharmaceutical entity used the 307 Hospital of the PLA (307 医院) as the setting for a cancer therapeutic clinical trial.”

Such work not only carries risks of sensitive technology falling into the CCP’s hands, “there are also U.S. biopharmaceutical trials listed on clinicaltrials.gov that were conducted with hospitals located in the XUAR, where credible investigative reports have shown that ethnic minorities in the region are repeatedly forced by the CCP to surrender their body autonomy. As we know, there is simply no ability for firms to conduct due diligence to ensure that clinical trials done in XUAR are voluntary.”

Axios noted that the trials in question concern Pfizer’s kidney cancer drug axitinib (brand name Inlyta), and Eli Lilly’s Alzheimer’s drug donanemab (brand name Kisunla).

The lawmakers asked the FDA to answer several questions related to its knowledge and oversight of such trials and called on the agency to “take on a greater role in protecting U.S. national security interests. With this data, it is clear that the FDA should play a greater role in analyzing U.S. biopharma entities (sic) clinical trial operations in the PRC.”

Pfizer responded that it “is committed to conducting business in an ethical and responsible manner. This includes respecting internationally recognized human rights throughout our operations,” Straight News reported. Eli Lilly claimed that it is “committed to IP protections, and we conduct robust assessments of our partners to ensure they meet Lilly standards for research and data privacy. Further, we oversee their activities when conducting clinical trials to ensure quality and data integrity.”

large body of evidence has found that mass restrictions on personal and economic activity undertaken in 2020 and part of 2021 caused far more harm than good in terms of personal freedom and economics as well as public health, particularly through the controversial COVID vaccines rushed through development by Pfizer, Moderna, Johnson & Johnson, and the Trump administration.

Yet, so far Big Pharma has largely escaped accountability thanks to the federal Public Readiness and Emergency Preparedness (PREP) Act of 2005. According to the Congressional Research Service (CRS), the PREP Act empowers the federal government to “limit legal liability for losses relating to the administration of medical countermeasures such as diagnostics, treatments, and vaccines.” Near the beginning of the 2020 COVID-19 outbreak, the Trump administration invoked the Act in declaring the virus a “public health emergency.”

Under this “sweeping” immunity, CRS explained, the federal government, state governments, “manufacturers and distributors of covered countermeasures,” and licensed or otherwise-authorized health professionals distributing those countermeasures are shielded from “all claims of loss” stemming from those countermeasures, with the exception of “death or serious physical injury” brought about through “willful misconduct,” a standard that, among other hurdles, requires the offender to have acted “intentionally to achieve a wrongful purpose.”

A handful of states are currently making efforts to hold Pharma companies accountable despite this hurdle, such as Florida’s ongoing grand jury investigation into the vaccines’ manufacturers, and a Kansas lawsuit accusing Pfizer of misrepresentation for calling the shots “safe and effective.”

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

Automotive

Ford Files Patent to Surveil Drivers

Published on

News release from Armstrong Economics

By Martin Armstrong

Governments are pushing the public to switch to smart vehicles to reduce fossil fuel consumption, but there is also a second motive – surveillance.

This September, Ford filed a new patent to eavesdrop on riders. They plan to share this information with third-parties to personalize the advertisements riders hear. Ford will also take the driver’s destination into consideration to determine location-specific advertisements and suggestions. The technology will factor in the weather, traffic, and all external sensors to fine tune when and what to market to passengers.

Advertisements are perhaps the least ominous use of voice data based on the plans that these car manufacturers have. Car insurance rates in the United States spiked 26% in the past year, which is partly due to car manufacturers sharing ride data with insurance companies. Even older cars with basic features like OnStar have tracking devices that report your driving behavior to the manufacturers who share your data with insurance companies and, ultimately, the government. LexisNexis, which tracks drivers’ behaviors and compiles risk profiles, has been sharing individual data with General Motors, who passes that information along to the insurance companies. General Motors.

One driver demanded that LexisNexis send him his personal report, which was a 258-page document containing every trip he or his wife took in his vehicle over a six-month period. LexisNexis said that this data will be used “for insurers to use as one factor of many to create more personalized insurance coverage.” They even reported small issues such as hard breaking and rapid acceleration, according to the report. “I don’t know the definition of hard brake. My passenger’s head isn’t hitting the dash,” an unnamed Cadillac driver enrolled in the OnStar Smart Driver subscription service told reporters.

“Cars have microphones and people have all kinds of sensitive conversations in them. Cars have cameras that face inward and outward,” a researcher with Mozilla Foundation told the Los Angeles Times. In fact, 19 automakers in 2023 admitted that they have the ability to sell your personal data without notice. Law enforcement may subpoena these records as well.

Ford claims that the patent was submitted, but they do not necessarily plan to use the technology. “Submitting patent applications is a normal part of any strong business as the process protects new ideas and helps us build a robust portfolio of intellectual property. The ideas described within a patent application should not be viewed as an indication of our business or product plans. No matter what the patent application outlines, we will always put the customer first in the decision-making behind the development and marketing of new products and services,” Ford said in a statement released to MotorTrend.

Now, the US Department of Transportation is permitted to mandate that certain manufacturers provide them with vehicle data. Sens. Ron Wyden of Oregon and Edward Markey of Massachusetts testified that all vehicles in the United States with a GPS or emergency call system are collecting travel data that car manufacturers have remote access to via the computer chips. The computer chips are compiling data on vehicle speed, movement, travel, and even using exterior sensors and cameras to record the vehicle’s location.

All of this violates the Fourth Amendment which protects against unreasonable searches and seizures without probable cause. These car manufacturers are surpassing what anyone would consider a reasonable expectation of privacy. Governments, third-party advertisement companies, and insurance companies all have warrantless access to personal data, and drivers are largely unaware they are being spied on. Section 702 of the Foreign Intelligence Surveillance Act permits the government to have backdoor access to this data.

The aforementioned senators’ concerns fell on deaf ears at the Federal Trade Commission. The Department of Transportation clearly is not listed within the US Constitution. People are already experiencing stiff consequences from autos sharing data with the sharp uptick in insurance rates.

Continue Reading

Business

Companies Are Getting Back To Business And Backing Away From DEI

Published on

From the Daily Caller News Foundation

By Devon Westhill

 

Classic American companies like John DeereHarley Davidson and Tractor Supply Co. are finally reevaluating Diversity, Equity, and Inclusion (DEI) initiatives. They are realizing that their consumers, many from rural, midwestern and working-class communities, don’t care for the DEI practices of corporate elites. They just want good service, reliable tractors and badass motorcycles.

The about-face is especially timely as the Supreme Court’s 2023 affirmative action decision prohibiting race-based college admissions has increased scrutiny of private sector DEI practices. This new legal climate, combined with the discovery of problematic DEI programs at major American companies, means that corporations are at long last feeling significant pressure to prioritize excellence and efficiency over faddish diversity metrics.

Companies operating in the free market have one purpose: to provide quality goods and services to consumers in order to make a profit. For too long, much of corporate America has focused on virtue signaling to appease the left’s cultural mandates. Now, business incentives are forcing a return to the bottom line.

The change began in June when conservative commentator Robby Starbuck took to social media to expose companies masquerading as all-American brands with traditional values. He first exposed Tractor Supply’s DEI practices and announced that he would be investigating a list of other companies considered exemplars of Americana.

In response, Tractor Supply customers began boycotting the company, resulting in an 8% decrease in its stock price (a $2.8 billion market value loss) over five days. This led Tractor Supply to announce later that month the termination of its DEI programming. The company promised to stop submitting data for the Human Rights Campaign’s Corporate Equality Index and withdrew sponsorship of LGBTQ+ pride events and voting campaigns, calling them “nonbusiness activities.”

Starbuck’s later exposure of John Deere’s DEI policies also caused the company to issue a statement announcing major cutbacks to their DEI programs. Harley DavidsonJack Daniels and Lowe’s followed suit, preemptively terminating their DEI programs and standards.

All of these companies should be commended for abandoning excessive DEI and getting back to business.

Now, instead of requiring costly, time-intensive programs to prove their liberal bona fides, they can focus on delivering results for their customers. Free from worry about optics and bureaucratic compliance, they can hire the most qualified employees and let them rise to the top.

But these decisions are not without their naysayers. DEI proponents have labeled these moves as bullying from far-right extremists and claim that terminating these policies will encourage gender and race discrimination in the workplace.

This hysteria is unwarranted and relies on the absurd claim that without DEI standards, there can be no equality, inclusion or respect in the workplace. Of course, it is crucial that businesses cultivate a culture of respect and dignity. Employees should be educated on their protections and duties regarding civil rights and basic civility in the workplace. All of the companies reversing on DEI have remained committed to fostering respectful, safe cultures for their employees.

In fact, too much corporate DEI can wreak havoc on a company’s morale. In many cases, it can result in scapegoating certain groups of people for grievous wrongs none of them had a hand in committing. It can also lead to damaging intellectual conformity and groupthink. DEI hiring quotas, in particular, can lead to serious legal risk. All of this results in the complete opposite of DEI’s purported goals. Instead, it increases workplace disunity and harms true diversity.

Ultimately, the DEI policies at these classic American companies have proven to only burden corporations, frustrate employees and confuse customers. Companies should prioritize producing better quality products, lowering prices, and offering attractive wages and benefits for all employees, instead of pouring time and money into ineffective policies that do not represent the American values of their customer base. So long, discrimination disguised as diversity.

Devon Westhill is the president and general counsel for the Center for Equal Opportunity.

 

Continue Reading

Trending

X